1561507
USP
磷酸伯安喹
United States Pharmacopeia (USP) Reference Standard
别名:
8-(4-氨基-1-甲基丁氨基)-6-甲氧基喹啉 二磷酸盐, 伯氨喹 二磷酸盐
登录查看公司和协议定价
选择尺寸
关于此项目
经验公式（希尔记法）:
C15H21N3O · 2H3PO4
化学文摘社编号:
分子量:
455.34
Beilstein:
3812133
MDL编号:
UNSPSC代码:
41116107
PubChem化学物质编号:
NACRES:
NA.24
等级
pharmaceutical primary standard
API类
primaquine
制造商/商品名称
USP
mp
205-206 °C (dec.) (lit.)
应用
pharmaceutical (small molecule)
包装形式
neat
储存温度
2-8°C
SMILES字符串
OP(O)(O)=O.OP(O)(O)=O.COc1cc(NC(C)CCCN)c2ncccc2c1
InChI
1S/C15H21N3O.2H3O4P/c1-11(5-3-7-16)18-14-10-13(19-2)9-12-6-4-8-17-15(12)14;2*1-5(2,3)4/h4,6,8-11,18H,3,5,7,16H2,1-2H3;2*(H3,1,2,3,4)
InChI key
GJOHLWZHWQUKAU-UHFFFAOYSA-N
正在寻找类似产品? 访问 产品对比指南
一般描述
This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the issuing Pharmacopoeia.For further information and support please go to the website of the issuing Pharmacopoeia.
应用
Primaquine phosphate USP reference standard, intended for use in specified quality tests and assays as specified in the USP compendia.
Also, for use with USP monograph such as Primaquine Phosphate Tablets.
Also, for use with USP monograph such as Primaquine Phosphate Tablets.
分析说明
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
其他说明
Sales restrictions may apply.
警示用语：
Danger
危险声明
危险分类
Acute Tox. 3 Oral - Muta. 2 - Repr. 2
储存分类代码
6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
Tamar E Carter et al.
The American journal of tropical medicine and hygiene, 91(2), 412-414 (2014-06-04)
Haiti is one of two remaining malaria-endemic countries in the Caribbean. To decrease malaria transmission in Haiti, primaquine was recently added to the malaria treatment public health policy. One limitation of primaquine is that, at certain doses, primaquine can cause
N P Dhammika Nanayakkara et al.
Antimicrobial agents and chemotherapy, 58(8), 4737-4744 (2014-06-11)
Hematotoxicity in individuals genetically deficient in glucose-6-phosphate dehydrogenase (G6PD) activity is the major limitation of primaquine (PQ), the only antimalarial drug in clinical use for treatment of relapsing Plasmodium vivax malaria. PQ is currently clinically used in its racemic form.
Improving the radical cure of Plasmodium vivax malaria.
Ric N Price
The American journal of tropical medicine and hygiene, 91(1), 3-4 (2014-04-23)
Stefanie C P Lopes et al.
The Journal of infectious diseases, 209(9), 1403-1407 (2014-01-15)
There is now a growing body of evidence that challenges the current view that Plasmodium vivax-infected erythrocyte (Pv-iE) are unable to sequester. Here we used ex vivo adhesion assays with Pv-iE before and after maturation to demonstrate a higher binding
Salomón Durand et al.
The American journal of tropical medicine and hygiene, 91(1), 18-26 (2014-04-23)
We evaluated the efficacy of three primaquine (PQ) regimes to prevent relapses with Plasmodium vivax through an open-label randomized trial in Loreto, Peru. Vivax monoinfections were treated with chloroquine for 3 days and PQ in three different regimes: 0.5 mg/kg
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持